As of November 6, 2026, ProMIS Neurosciences Inc. is a publicly traded company (Nasdaq: PMN); its largest reported holder is Janus Henderson, with 14.4% on Schedule 13G of April 7, 2026, then Deep Track Capital (9.99%). The largest insider holding is Jeremy M. Sclar, a 10% owner, with 7,246,296 shares (80.8% of shares outstanding), per Form 4 of September 8, 2025 (Schedule 13G, April 7, 2026).
Is this your company?
About to sign with, pay or invest in ProMIS Neurosciences Inc.? See the free Snapshot first.
Free to see. No signup.
Is ProMIS Neurosciences Inc. a real, registered company?
- ProMIS Neurosciences Inc. files with the SEC under CIK 1374339 (its SEC filings).
- Its shares are listed under the ticker PMN on Nasdaq (SEC company record).
- Incorporated in Z4; business address in Toronto, A6, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ProMIS Neurosciences Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Great Point Partners, LLC (filed 2026-08-14).
Who are ProMIS Neurosciences Inc.'s owners and officers?
ProMIS Neurosciences Inc.: business address in Toronto, A6; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer (Form D, 2022-10-21)
- : Executive Officer, Director (Form D, 2022-10-21)
- : Executive Officer (Form D, 2022-10-21)
- : Executive Officer (Form D, 2022-10-21)
- : Executive Officer (Form D, 2022-10-21)
- : Director (Form D, 2022-10-21)
- : Director (Form D, 2022-10-21)
- : Director (Form D, 2022-10-21)
- : Director (Form D, 2022-10-21)
- : Director (Form D, 2022-10-21)
- : Director (Form D, 2022-10-21)
- : Director (Form D, 2022-10-21)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Great Point Partners, LLC | 7.66% |
| Schedule 13G/A, 2026-08-13 | Wellington Biomedical Innovation Master Investors (Cayman) Ii, L.P. | 7.8% |
| Schedule 13G/A, 2026-08-13 | Wellington Management Group LLP | 7.8% |
| Schedule 13G, 2026-05-15 | Great Point Partners, LLC | 9.99% |
| Schedule 13G, 2026-05-15 | Wellington Management Group LLP | 10% |
| Schedule 13G/A, 2026-05-07 | Michael S. Gordon | 2% |
| Schedule 13G, 2026-04-07 | Janus Henderson Group PLC | 14.4% |
| Schedule 13G, 2026-03-18 | Wellington Biomedical Innovation Master Investors (Cayman) Ii, L.P. | 9.99% |
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 0.93% |
| Schedule 13G/A, 2026-02-17 | Great Point Partners, LLC | 9.99% |
| Schedule 13G, 2026-02-10 | Trails Edge Capital Partners, LP | 9.9% |
| Schedule 13G, 2026-02-06 | Deep Track Capital, LP | 9.99% |
Questions about who owns ProMIS Neurosciences Inc.
Who owns ProMIS Neurosciences Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of ProMIS Neurosciences Inc.: Janus Henderson Group PLC (14.4%, Schedule 13G, filed 2026-04-07), Deep Track Capital, LP (9.99%, Schedule 13G, filed 2026-02-06), Trails Edge Capital Partners, LP (9.9%, Schedule 13G, filed 2026-02-10), Wellington Biomedical Innovation Master Investors (Cayman) Ii, L.P. (7.8%, Schedule 13G/A, filed 2026-08-13) and Wellington Management Group LLP (7.8%, Schedule 13G/A, filed 2026-08-13); 1 more is listed above.
Who are the largest shareholders of ProMIS Neurosciences Inc.?
By the share each holder's latest filing reports, the largest holders of ProMIS Neurosciences Inc. on this page are Janus Henderson Group PLC (14.4%), Deep Track Capital, LP (9.99%) and Trails Edge Capital Partners, LP (9.9%).
When did Janus Henderson Group PLC buy into ProMIS Neurosciences Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group PLC on this page is the Schedule 13G, filed 2026-04-07, reporting 14.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on ProMIS Neurosciences Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ProMIS Neurosciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ProMIS Neurosciences Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own ProMIS Neurosciences Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 7,246,296 shares (80.8% of shares outstanding), 65,000 held directly and 7,181,296 indirectly (Form 4, 2025-09-08).
- Shaf QIC LLC, a 10% owner: 5,184,760 shares (57.8% of shares outstanding), on a joint filing (Form 3, 2025-08-14).
- , a 10% owner: 5,184,760 shares (57.8% of shares outstanding), on a joint filing (Form 3, 2025-08-14).
- Jeremy M. Sclar 2012 Irrevocable Family Trust, a 10% owner: 3,710,459 shares (41.4% of shares outstanding) (Form 4, 2025-09-30).
- Michael S. Gordon: 2,435,029 shares (27.2% of shares outstanding), held indirectly through a title 19 acies (Form 4, 2025-08-14).
Shares outstanding: 8,967,693 as of 2026-08-13, from the company's latest SEC cover page.
How much has ProMIS Neurosciences Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2022-10-21 | $7.47M | $10.07M |
Keep reading
More on ProMIS Neurosciences Inc. and the records around it.
ProMIS Neurosciences Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- ABG Management Ltd. also filed stake reports on 2 other companies: Whitehawk Therapeutics, Inc. (Aug 2026), Ceribell, Inc. (Dec 2025)
- Sphera Funds Management Ltd. also filed stake reports on 2 other companies: Tenax Therapeutics, Inc. (Oct 2026), Outlook Therapeutics, Inc. (Feb 2026)
- Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. also filed stake reports on 2 other companies: Korsana Biosciences, Inc. (Sep 2026), MBX Biosciences (Nov 2025)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/promis-neurosciences